IceCure Medical Revenue and Competitors
Estimated Revenue & Valuation
- IceCure Medical's estimated annual revenue is currently $23.1M per year.
- IceCure Medical received $5.5M in venture funding in February 2015.
- IceCure Medical's estimated revenue per employee is $251,000
- IceCure Medical's total funding is $48M.
- IceCure Medical has 92 Employees.
- IceCure Medical grew their employee count by 3% last year.
IceCure Medical Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is IceCure Medical?
IceCure Medical is a medical device company, with US operations in Collierville, TN. Our parent company, IceCure Medical, LTD was founded in 2006 and is located in Ceseara, Israel. IceCure Medical develops and markets minimally invasive cryoablation therapies for benign and malignant tumors. Our proprietary ProSense system provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma. The ProSense procedure is an attractive alternative to the current standard treatment of open surgical excision. The ProSense procedure uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to destroy (ablate) the targeted tumor in-situ. The ProSense cryoablation procedure is a safe and effective treatment option that can be performed in 10-15 minutes in the comfort of a doctor's office. We are currently conducting the ICE3 Clinical trial for the non-surgical treatment of breast cancer. There are 20 sites intially participating in this trial where certain small breast cancers will be treated with cryoablation then followed for 5 years. This allows women to be treated for their breast cancer with out surgery. IceCure support of patients and physicians through its Breast Health Options advocacy program embodies its firm commitment to offer affordable care. For more information, visit www.icecure-medical.com, www.breasthealthoptions.com, and @CoverCryo on Twitter.keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
IceCure Medical News
Ra Medical Systems (NYSE:RMED) and IceCure Medical (NASDAQ:ICCM) Head to Head Analysis. Posted by admin on Apr 25th, 2022.
This table compares IceCure Medical and Venus Concept's top-line revenue, earnings per share (EPS) and valuation. Gross Revenue, Price/Sales...
Financial Survey: IceCure Medical (NASDAQ:ICCM) vs. Westaim (OTCMKTS:WEDXF). Posted by admin on Apr 23rd, 2022. Share on Twitter Share on Facebook Share on...
CAESAREA, Israel, Sept. 1, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced it has entered into an initial distribution ...
CAESAREA, Israel, Aug. 26, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its ordinary shares have been approved ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
IceCure Medical Funding
|2015-02-24||$5.5M||Undisclosed||Epoch Partner Investments||Article|